“…All experiments were performed in triplicate and images shown are representative examples. Immunofluoresence, to detect BrdU incorporation, was performed as described (Dimitrova et al, 1999). Antibodies used were p300 N-terminal (N-15) p300 C-terminal (C-20), CBP (A-22), p53 (DO-1), RB, (C-15), RB (IF8), c-myc (9E10) (Santa Cruz Biotechnologies, Santa Cruz, USA); p21 WAF1 (Ab-1) (Oncogene Research Products, San Diego, USA); phospho-RB (Ser807/ 811), pan-acetyl-lysine (monoclonal) (Cell Signalling Technologies, Hitchin, UK); cyclin A (6E6), cyclin D1 (P2D11F11), cyclin E (G2a), mcm2 (G1) (Novocastra, Newcastle-upon-Tyne, UK); b-actin (AC-15) (Abcam, Cambridge, UK); fluorescein isothiocyanate (FITC)-BrdU (N1031) (BD Biosciences, Oxford, UK); and BrdU (Cell Proliferation Kit) (Amersham, Pollards Wood, UK).…”